Niosomal encapsulation of the antitubercular drug, pyrazinamide

Drug Development and Industrial Pharmacy

Volumn 37, Issue 9, 2011, Pages 1110-1118

  El Ridy, Mohammed Shafik ^a   Abdelbary, Ahmed ^b   Nasr, Essam Amin ^c   Khalil, Rawia Mohammed ^a   Mostafa, Dina Mahmoud ^a   El Batal, Ahmed Ibrahim ^d   Abd El Alim, Sameh Hosam ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Agricultural Research Center   (Egypt)

^d NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

Author keywords

Biological evaluation; Characterization; Niosomes; Pyrazinamide; Tuberculosis

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; LIPOSOME; NIOSOME; OCTADECYLAMINE; PYRAZINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CALORIMETRY; CENTRIFUGATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; ELECTRON MICROSCOPY; ENCAPSULATION; FEMALE; GAMMA IRRADIATION; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MALE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; REVIEW; SPECTROPHOTOMETRY;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG CARRIERS; FEMALE; GUINEA PIGS; HYDROGEN-ION CONCENTRATION; LIPOSOMES; MALE; MYCOBACTERIUM TUBERCULOSIS; PARTICLE SIZE; PYRAZINAMIDE; STATISTICS AS TOPIC; TUBERCULOSIS;

EID: 79961145930     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.560605     Document Type: Review

References (31)

1. Ducati RG, Rufno-Netto A, Basso LA, Santos DS. (2006). Te resumption of consumption-a review on tuberculosis. Mem Inst Oswaldo Cruz, 101:697-714.
2. World Health Organization. (2007). WHO report 2007: Global tuberculosis control.
3. Elston JW, Taker HK. (2008). Co-infection with human immunodefciency virus and tuberculosis. Indian J Dermatol Venereol Leprol, 74:194-199.
4. Mitchison DA. (1985). Te action of antituberculosis drugs in short-course chemotherapy. Tubercle, 66:219-225. (Pubitemid 16150082)
5. Zhang Y, Mitchison D. (2003). Te curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis, 7:6-21.
6. Heifets L, Lindholm-Levy P. (1992). Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis, 145:1223-1225.
7. Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Coll Interface Sci, 58:1-55.
8. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. (1985). Te preparation and properties of niosomes-non-ionic surfactant vesicles. J Pharm Pharmacol, 37:863-868.
9. Hunter CA, Dolan T F, Coombs GH, Baillie AJ. (1988). Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol, 40:161-165.
10. Namdeo A, Jain NK. (1996). Niosomes as drug carriers. Ind J Pharm Sci, 58:41-46. (Pubitemid 26178433)
11. Baillie AJ, Coombs GH, Dolan T F, Laurie J. (1986). Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol, 38:502-505. (Pubitemid 16081869)
12. British pharmacopoeia. (2007). Pyrazinamide. Stationary ofce, London. pp. 2879.
13. El-Ridy MS, Ammar HO, Ghorab M, Ghorab MM. (1994). Evaluation of the antischistosomal efect of praziquantel in a liposomal delivery system in mice. Int J Pharm, 103:237-241. (Pubitemid 24073684)
14. El-Ridy MS, Khalil RM, Moustafa DM, El-Rashdy MM, Osman A, Monem AS. (1997). Chemoprophylaxis of schistosomiasis using liposome encapsulated oxamniquine. Drug Dev Ind Pharm, 23:771-782. (Pubitemid 27325705)
15. El-Ridy MS, Mostafa DM, Abdel-Alim SH, Abdelbary A. (2006). Liposomal encapsulation of the tuberculocidal drug, pyrazinamide, for increasing safety and potency. Egypt Pharm J, 5:29-43.
16. El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd El-Alim S. (2007). Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm, 330:82-88. (Pubitemid 46097363)
17. Bangham AD, Horne RW. (1964). Negative staining of phospholipids and their structural modifcation by surface-active agents as observed in the electron microscope. J Mol Biol, 8:660-668.
18. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. (2003). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother, 52:981-986. (Pubitemid 38008419)
19. Pandey R, Khuller GK. (2004). Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother, 53:635-640. (Pubitemid 38499780)
20. Orozco LC, Quintana FO, Beltrán RM, de Moreno I, Wasserman M, Rodriguez G. (1986). Te use of rifampicin and isoniazid entrapped in liposomes for the treatment of Murine tuberculosis. Tubercle, 67:91-97. (Pubitemid 16080226)
21. Marks J. (1972). Ending the routine guinea-pig test. Tubercle, 53:31-34.
22. Parisi AN, Antoine AD. (1975). Characterization of Bacillus pumilus E601 spores after single sublethal gamma irradiation treatments. Appl Microbiol, 29:34-39.
23. Juliano RL, Stamp D. (1978). Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol, 27:21-27. (Pubitemid 8239564)
24. Cable C. (1989). An examination of the efects of surface modifcations on the physicochemical and biological properties of non-ionic surfactant vesicles. PhD Tesis, University of Strathclyde, Glasgow, UK.
25. Junyaprasert VB, Teeranachaideekul V, Supaperm T. (2008). Efect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS Pharmscitech, 9:851-859.
26. Deol P, Khuller GK, Joshi K. (1997). Terapeutic efcacies of isoniazid and rifampin encapsulated in lung-specifc stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother, 41:1211-1214. (Pubitemid 27231415)
27. Falk R, Randolph TW, Meyer JD, Kelly RM, Manning MC. (1997). Controlled release of ionic compounds from poly (L-lactide) microspheres produced by precipitation with a compressed antisolvent. J Contr Rel, 44:77-85. (Pubitemid 27051336)
28. Jain CP, Vyas SP. (1995). Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencapsul, 12:401-407.
29. Gaur PK, Mishra S, Gupta VB, Rathod MS, Purohit S, Savla BA. (2010). Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome. Drug Dev Ind Pharm, 36:638-646.
30. Kamath MP, Shenoy BD, Tiwari SB, Karki R, Udupa N, Kotian M. (2000). Prolonged release biodegradable vesicular carriers for rifampicin-formulation and kinetics of release. Indian J Exp Biol, 38:113-118. (Pubitemid 30091961)
31. Jain CP, Vyas SP, Dixit VK. (2006). Niosomal system for delivery of rifampicin to lymphatics. Ind J Pharm Sci, 68:575-578. (Pubitemid 46087763)